Previous 10 | Next 10 |
NEW YORK, NY, June 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc . (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and...
NEW YORK, NY, June 18, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine an...
REHOVOT, Israel, June 17, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced that CEO Herman Weiss, MD, MBA, FA...
New York, NY, June 13, 2019 (GLOBE NEWSWIRE) -- via NEWEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ...
New York, NY, June 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and...
TM-B1 demonstrates 80% accuracy vs. 50% accuracy for current gold standard Todos Medical to attend 2019 ASCO Annual Meeting in Chicago, IL REHOVOT, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF) ( http://www.Todosmedical.com ) today announced positive res...
New York, NY, May 31, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ophth...
New York, NY, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarantus Bioscience Holdings, Inc. (OTC Pink: AMBS) (the “Company,” or AMBS), a US-based JLABS-alumnus biotechnology holding company developing first-in-class orphan neurologic, regenerative medicine and ...
- Data demonstrated strong correlation between LymPro and amyloid PET - Todos to present at Alzheimer’s Solutions Conference on June 3, 2019 in Philadelphia - Todos to present at LD Micro on June 4 th , 2019 REHOVOT, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Todos Med...
REHOVOT, Israel, May 23, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, such as Alzheimer's disease, today announced t...
News, Short Squeeze, Breakout and More Instantly...
Amarantus BioScience Holdings Inc Company Name:
AMBS Stock Symbol:
OTCMKTS Market:
Amarantus BioScience Holdings Inc Website:
Board Member/Acting CEO Provides Shareholder Update Sale of Engineered Skin Substitute (ESS) subsidiary, Cutanogen Corporation. Emphasis placed on advancing Elto Pharma, Inc. and MANF Therapeutics programs NEW YORK, NY / ACCESSWIRE / April 27, 2022 / Amarantus Bioscience Hol...
Significant progress in establishing COVID-19 PCR-based diagnostic testing business in US 3CL Protease-based saliva test making progress in Israel 3CL Protease inhibitor NLC-001 dietary supplement added to commercial portfolio 2019 convertible note holders and instituti...
NLC-001 is a proprietary blend of plant extracts administered orally as dietary supplement US FDA granted Certificate of Free Sale for NLC-001 on August 28, 2020 JV evaluating potential of NLC-001 to treat COVID-19 in clinical studies in Israel Todos e...